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OPINION
Grey zone between narcolepsy type 1 
and type 2
Zona cinzenta entre narcolepsia tipo 1 e tipo 2
Dear Editor,
The third International Classification of Sleep Disorders 
(ICSD-3) defines narcolepsy as patients with periods of sleep 
attacks or excessive daytime sleepiness. Neurophysiology 
tests with unremarkable polysomnography and positive 
Multiple Sleep Latency Test scores establish the diagnosis 
of narcolepsy1.
The difficulties in the differential diagnosis include sec-
ondary causes of excessive daytime sleepiness, narcolepsy, 
and other primary central hypersomnia disorders1. Usually, 
narcolepsy type 1 is differentiated by the presence of immu-
nological pathophysiology and the consequent lower levels of 
hypocretin-12.
Usually, narcolepsy type 1 patients have cataplexy and 
a CSF hypocretin-1 concentration ≤ 110 pg/mL or < 1/3 of 
mean values obtained in normal volunteers.2 Interestingly, 
the ICSD-3 defines patients with excessive daytime sleepi-
ness and lower CSF hypocretin-1 levels as having type 1 nar-
colepsy, even without cataplexy. In fact, measuring CSF levels 
of hypocretin-1 has been considered the best option for the 
diagnosis of type 1 narcolepsy1.
However, the normal levels of hypocretin-1 are higher than 
200 pg/mL2. Indeed, there is a grey zone between 110 pg/mL 
and 200 pg/mL that is not discussed in the literature.
We describe three patients with hypocretin-1 levels 
between 110 pg/mL and 200 pg/mL (Table). All had the pres-
ence of allele HLA-DQB1*0602, sleep hallucinations, and sleep 
paralysis. Two patients had all the criteria for narcolepsy type 1, 
but one of them did not have all the criteria for narcolepsy.
The hypocretin-1 threshold of 110 pg/mL has been identi-
fied by two studies2. Quality Receiver Operating Characteristic 
curve analysis indicates a threshold of 200 pg/mL and 
150 mg/mL for direct and extracted assays in volunteers, 
respectively3,4. Although the biomarkers for identification of 
type 1 narcolepsy are very useful, the identification of patients 
with narcolepsy type 2 is still a challenge in many cases.
A paper written by Barateau et al. entitled Comorbidity 
between central disorders of hypersomnolence and immune-based 
disorders, expands this discussion.5 They state that the prev-
alence of immune diseases, inflammatory disorders, and 
allergies are not higher in narcolepsy type 1. Interestingly, 
autoimmune diseases were higher in narcolepsy type 2 
patients and inflammatory disorders were common in 
idiopathic hypersomnolence. 
Clinical and neurophysiology characteristics, genetics 
and hypocretin-1 levels are not sufficient to define narcolepsy 
in all circumstances. Unfortunately, the description of a few 
patients cannot characterize a pattern, especially in atypi-
cal cases. Further efforts to study patients with hypocretin-1 
between 110 pg/mL and 200 pg/mL should help to classify 
them. It is possible that, in the future, biomarkers of inflam-
mation and immune responses will be useful for that.
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Table.  Demographic, clinical, genetic, and hypocretin-1 characteristics.
Age HLA-DQB1*0602 CSF-HCRT (pg/mL)
MSLT/Average 
latency/(min) MSLT/SOREMP Cataplexy
Sleep 
paralysis Hallucinations
Automatic 
behavior
Disruptive 
sleep
49 Yes 135.4 1 4 Yes Yes Yes No Yes
23 Yes 139.49 4 1 No Yes Yes No No
40 Yes 140.65 5 4 Yes Yes Yes No Yes
CSF: cerebrospinal fluid; HCRT: hypocretin; MSLT: Multiple Sleep Latency Test;  SOREMP: sleep onset rapid eye moment period; min: minutes.
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